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Abstract: Background: The blood-brain barrier restricts drug penetration to the central nervous system. Targeted 
nanocarriers are new potential tools to increase the brain entry of drugs. Ligands of endogenous transporters of 
the blood-brain barrier can be used as targeting vectors for brain delivery of nanoparticles.  
Objective: We tested biotin-labeled solid nanoparticles for the first time and compared to biotinylated glu-
tathione-labeled nanoparticles in brain endothelial cells. 
Method: Neutravidin coated fluorescent polystyrene nanoparticles were derivatized with biotin and biotinylated 
glutathione. As a human in vitro blood-brain barrier model hCMEC/D3 brain endothelial cells were used. Cell 
viability by MTT test, uptake and transfer of the nanoparticles across the endothelial monolayers were measured. 
The uptake of the nanoparticles was visualized by confocal microscopy. 
Results: The tested nanoparticles caused no change in cell viability. The uptake of biotin- and glutathione-labeled 
nanoparticles by brain endothelial cells was time-dependent and significantly higher compared to non-labeled 
nanoparticles. The penetration of the glutathione-labeled nanoparticles across the endothelial monolayer was 
higher than the biotin-targeted ones. Biotin- and glutathione-targeted nanoparticles were visualized in 
hCMEC/D3 cells. We verified that hCMEC/D3 express mRNA for sodium-dependent multivitamin transporter 
(SMVT/SLC5A6) responsible for the blood-brain barrier transport of biotin. 
Conclusion: Biotin as a ligand increased the uptake and the transfer of nanoparticles across brain endothelial 
cells. Biotinylated glutathione could further increase nanoparticle permeability through endothelial monolayers 
supporting its use as a brain targeting vector. 
Keywords: Biotin, blood-brain barrier, brain endothelial cell, glutathione, solute carriers, solid nanocarriers, targeted nanoparticle. 
1. INTRODUCTION 
 Pharmaceutical treatment of most disorders of the central nerv-
ous system (CNS), like neurodegenerative diseases, stroke or brain 
tumors, is far from satisfactory due to the poor penetration of thera-
peutic drugs to the brain [1]. The blood-brain barrier (BBB) is a 
major obstacle to prevent potential neuropharmaceuticals, espe-
cially new biopharmacons, nucleic acids, peptide or protein drugs, 
to reach their targets in the CNS [2]. The barrier is formed by brain 
endothelial cells lining the cerebral capillaries, and plays an impor-
tant role in the homeostatic regulation of the brain microenviron-
ment necessary for the stable and co-ordinated activity of neurons 
[3]. The major mechanisms at the level of the BBB to limit drug 
transport are the complex intercellular tight junctions (TJs) between 
brain endothelial cells restricting the paracellular permeability, the 
low level of non-specific vesicular transendothelial transport, and 
efflux transporters which deliver metabolites from brain to blood 
and prevent the entry of xenobiotics and drugs to the CNS [3, 4]. 
The restricted paracellular and transendothelial transport pathways 
result in the low CNS entry of hydrophilic drugs, while the active 
efflux transporters of brain endothelial cells limit the brain penetra-
tion of lipophilic drugs. There is a huge research effort to develop 
drug delivery systems for the CNS.  
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 In the last two decades the potential of nanoparticles (NPs) as 
drug carriers including vesicular and solid NPs is increasingly in-
vestigated for drug delivery across the BBB [5, 6]. The most suc-
cessful approaches target specifically the endogenous transport 
systems at the BBB. While the receptor-mediated transport systems 
of brain endothelial cells have been investigated as a way of drug 
delivery across the BBB for several decades [2] other physiological 
pathways, especially the carrier systems of the BBB have been 
studied only recently for CNS delivery [7]. Carrier-mediated trans-
port at the BBB is saturable, bi-directional and supplies the CNS 
with nutrients such as hexoses, amino acids, monocarboxylic acids, 
vitamins, nucleosides, purine and pyrimidine bases, fatty acids, 
ions, organic anions and organic cations [8]. About 40 members of 
the solute carrier (SLC) family were identified in brain microves-
sels by serial analysis of gene expression [9]. SLCs have been ne-
glected in biomedical research despite their huge number and their 
potential as drug and drug delivery targets [10].  
 In contrast to NPs targeted by antibodies or peptides for CNS 
delivery, there are only few papers describing NPs labeled with 
ligands of nutrient transporters present at the BBB. Gold NPs cova-
lently labeled with glucose, a ligand of hexose transporters was 
transferred better than unlabeled NPs across hCMEC/D3 human 
brain endothelial cell monolayers [11], a human in vitro BBB 
model [12, 13]. Although the paracellular tightness of hCMEC/D3 
cell line does not make it a suitable BBB model for small drug 
screening [13], it is widely used to study the penetration of NPs, 
which is a transcellular process [12]. Glucose analog-targeted ve-
sicular NPs were used successfully to deliver vasoactive intestinal 
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peptide to brain in mice [14]. Phenylalanine, a ligand of the large 
amino acid transporter-1 (LAT-1, SLC7A5), used as a vector to 
target solid lipid NPs increased the transfer of the anti-HIV agent 
efavirenz across a BBB model in vitro and the drug’s penetration to 
the brain of rats [15]. A delivery system based on dendrigraft con-
taining doxorubicin and targeted by a choline-derivate with high 
affinity to choline transporter (SLC44A1) was more cytotoxic to 
glioma cells both in vitro and in vivo than non-targeted NPs or 
doxorubicin alone [16].  
 Glutathione (GSH) is a promising new ligand of an endogenous 
BBB transporter for CNS drug delivery. This tripeptide with anti-
oxidant properties has a central role in the detoxification of intracel-
lular metabolites. GSH is actively transported across the BBB [17], 
but the molecular mechanism(s) and the BBB transporter(s) are not 
known. Based on these original observations Gaillard et al. devel-
oped a BBB delivery platform [18, 19]. Pegylated liposomes tar-
geted with GSH enhance the delivery of doxorubicin cargo across 
hCMEC/D3 brain endothelial cells and to brain tumors in mice 
[20]. Further studies confirmed the improved CNS delivery by glu-
tathione targeted NPs of doxorubicin [21] and the opioid peptide 
DAMGO [22] in animal models. GSH is the only BBB targeting 
ligand, that is part of a brain delivery platform successfully com-
pleting phase I/IIa clinical trial [18]. 
 Biotin (vitamin B7) is a ligand of the Na+-dependent multivita-
min transporter (SMVT/SLC5A6) which is responsible for the CNS 
transport of this water soluble vitamin across the BBB [8, 23]. Bio-
tin has long been used for ligation techniques, imaging and diagnos-
tics because of the strong interaction between biotin and avidin. 
Biotin-avidin technology has a potential to be applied for targeted 
drug therapy of tumors [24]. However, until now biotin was not 
tested as a potential targeting ligand of NPs to cross brain endothe-
lial cells. 
 The aim of our study was to investigate biotin as a targeting 
ligand for solid fluorescent NPs as a simplified test system in 
hCMEC/D3 brain endothelial cells, an in vitro BBB model. We 
compared the efficacy of biotin targeting to glutathione-labeled NPs 
as a reference ligand for CNS drug delivery via targeting endoge-
nous BBB transporter(s). In the present work unlabeled, biotin- and 
GSH-targeted NPs were prepared and characterized, and tested for 
cell viability, uptake and permeability in cultured brain endothelial 
cells. 
2. MATERIALS AND METHODS 
2.1. Materials 
 All reagents were purchased from Sigma-Aldrich Kft. Hungary 
(part of Merck Life Science), except for those specifically men-
tioned. 
2.2. Methods 
2.2.1. Synthesis of Biotinyl-6-aminohexanoyl-lysyl-glutathione 
 The N-terminal amino group of glutathione is positively 
charged at physiological pH. Acylation of this amino group with 
biotin would diminish this positive charge. To avoid the change of 
the overall charge of the molecule a lysine residue was built into the 
peptide. A 6-aminohexanoic acid spacer was also incorporated be-
tween the lysyl-glutathione and the biotin. Biotinyl-6-Ahx-Lys-
γGlu-Cys-Gly-OH peptide was synthesized on Fmoc-Gly-Wang 
resin in 0.25 mmolar scale. Fmoc group was removed by treating 
the resin with 20% piperidine in DMF first for 5 min then with a 
new portion of the above mentioned solution for 20 min. All Fmoc 
protected amino acids and biotin were coupled as follows: 1 mmole 
of the amino acid was activated with DCC/HOBt (1 mmole each) in 
DMF/DCM (1:1, v/v). The coupling time was 2 hours. The reaction 
was monitored with qualitative ninhydrin test. If the test was posi-
tive, the coupling was repeated using HATU/DIEA activation of the 
amino acid. The peptide was cleaved from the resin by treating the 
peptide-resin with a mixture containing TFA (90 v/v%), TIS (2 
v/v% ), DTT (4 m/v%) and water (4 v/v%) for 15 min at 0 ºC and 
for 1 hour 45 min at room temperature. The peptide was then pre-
cipitated with cold diethyl ether, filtered, washed with diethyl ether, 
dissolved and lyophilized. The product was analyzed and purified 
by HPLC. Analytical analysis was done on a Hewlett-Packard Ag-
ilent 1100 Series HPLC apparatus using a Luna C18 column (100 
Å, 5 µm, 250×4.60 mm, Phenomenex). Preparative chromatography 
was done on a Shimadzu HPLC apparatus equipped with a Luna 
C18 column (100 Å, 15 µm, 250×21.2 mm, Phenomenex). As elu-
ent A and eluent B 0.1 % TFA in d.d. water (Solvent A) and 80% 
ACN, 0.1% TFA in distilled water (Solvent B) was used, respec-
tively. 
2.2.2. Derivatization and Characterization of Nanoparticles  
 Neutravidin labeled 40 nm polystyrene red fluorescent nanopar-
ticles (TransFluoSpheres Fluorescent Microspheres, T8860, 
Thermo Fisher Scientific Inc., Waltham, MA USA) were used for 
the study. The nanoparticle suspension contained 1% solid of 7.8 
nmoles/mg bearing 8.23 mmole neutravidin functionality, the den-
sity of polystyrene was 1.055 g/cm3 in buffer (50 mM sodium 
phosphate, 50 mM NaCl, pH 7.5, 0.02% Tween 20, 5 mM azide). 
To label the nanoparticles 100 µL of suspension was incubated with 
30 µL distilled water containing 3 fold molar excess of biotinyl-6-
aminohexanoyl-lysyl-glutathione or biotin for 2 hours at room tem-
perature. The different groups of nanoparticles were prepared from 
different batches of TransFluoSpheres. The control, non-labeled 
solid nanoparticles (SNP) and the derivatized biotin-labeled (SNP-
B) and biotinylated glutathione-labeled (SNP-B-GSH) nanoparti-
cles were stored at 4 ºC until the experiments (Fig. 1). The nanopar-
ticles were characterized for particle size and zeta potential using 
dynamic light scattering (Malvern Zetasizer Nano ZS, Worcester-
shire, UK). Before measurements, the SNPs were diluted and the 
final concentrations were 0.15 mg/mL in phosphate buffered saline 
(PBS). The mean particle size and mean zeta potential values were 
calculated from three measurements per sample. 
2.2.3. Scanning Electron Microscopy  
 The morphology of nanoparticles was visualized by scanning 
electron microscopy (SEM; JEOL, JSM-7100F-LV, Akishima, 
Tokyo, Japan). Before SEM observation, a droplet of nanoparticles 
was diluted to 105 and 1 µL of the solution was pipeted onto a clean 
mica surface and then air-dried. After sputtering 8 nm gold on the 
sample, the nanoparticles were imaged in high vacuum mode at 5 
kV. 
2.2.4. Cell Culture 
 The human brain microvascular endothelial cell line 
hCMEC/D3 [12] was grown in MCDB 131 medium (Pan Biotech) 
supplemented with FBS (5%), GlutaMAX (100×, Life Technolo-
gies, USA), Chemically Defined Lipid Concentrate (100×, Life 
Technologies, USA), ascorbic acid (10 µg/mL), hydrocortisone 
(550 nM), heparin (100 µg/mL), bovine basic fibroblast growth 
factor (1 ng/mL, Roche, Switzerland), insulin (2.5 µg/mL), transfer-
rin (2.5 µg/mL), sodium selenite (2.5 ng/mL) and gentamicin (50 
µg/mL). hCMEC/D3 cells (passage number ≤ 35) were cultured for 
3-5 days until full confluency and received 10 mM lithium chloride 
(Merck, USA) 24 hours before experiments to induce BBB proper-
ties [25, 12].  
2.2.5. MTT Toxicity Assay 
 To test the viability and metabolic activity of brain endothelial 
cells after treatment with SNPs cellular reduction of the yellow 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
dye to formazan crystals was used [26]. Confluent cultures of brain 
endothelial cells in 96-well plates (Orange Scientific, Braine-
l’Alleud, Belgium) were treated with SNPs diluted in culture me-
dium in the concentration range of 0.01–1 mg/mL for 24 hours. 
Triton X-100 detergent (1 mg/mL) was used as a reference sub-
stance to determine the 100% cellular toxicity. After treatment 
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MTT solution (0.5 mg/ mL) was added to the wells for 3 hours at 
37°C. Formazan produced by living cells was dissolved in dimethyl 
sulfoxide. Absorbance was detected by a multiwell plate reader at 
570 nm (Fluostar Optima, BMG Labtechnologies, Ortenberg, Ger-
many). Cell viability and metabolic activity are reflected by the 
MTT dye conversion and was calculated as the percentage of dye 
reduction by culture medium treated (control) cells. 
2.2.6. Measurement of the Uptake of SNPs in Brain Endothelial 
Cells 
 Brain endothelial cell were seeded in 24-well plates (Corning 
Costar) at the density of 2×104 cells/well. After 3 days the confluent 
monolayers were incubated with 150 µg/mL SNP, SNP-B or SNP-
B-GSH for 4 or 8 hours at 37 ºC in a CO2 incubator. After incuba-
tion the cells were washed three times with ice cold PBS and lysed 
in 500 µL/well Triton X-100 detergent (10 mg/mL). To quantify the 
uptake of SNPs the fluorescence of cell lysates was measured with 
a spectrofluorometer (Horiba Jobin Yvon Fluorolog 3, Edison New 
Jersey, USA) at 488 nm excitation and 605 nm emission wave-
lengths.  
 To visualize the cellular uptake of the fluorescent particles 
brain endothelial cells were grown on collagen coated glass cover 
slips (VWR, USA) and treated with 150 µg/ml SNP, SNP-B or 
SNP-B-GSH for 24 hours. Cells were fixed with 4% paraformalde-
hyde in PBS for 30 min, washed three times with PBS then cell 
nuclei were stained with bis-benzimide (Hoechst dye 33342) for 10 
min. Samples were mounted with Fluoromount-G (Southern Bio-
tech, Birmingham, AL, USA), and examined with a confocal laser 
scanning microscope (Olympus Fluoview FV1000, Olympus Life 
Science Europa GmbH, Hamburg, Germany). 
2.2.7. Permeability Measurement 
 For permeability studies brain endothelial cells were seeded 
onto collagen coated 12-well tissue culture inserts (Transwell clear, 
polyester membrane, 0.4 µm pore size, Corning Costar, USA) and 
cultured for 5 days. Culture medium was changed and resistance 
checked every second day. The integrity of the monolayers was 
checked by Evans blue labeled bovine serum albumin (Mw: 67 
kDa) marker molecule. The cells were treated with 150 µg/mL 
SNP, SNP-B or SNP-B-GSH diluted in culture medium in the upper 
compartments (0.5 mL) for 8 hours. After incubation samples were 
collected from the lower compartments (1.5 mL) and measured 
with spectrofluorometer Horiba Jobin Yvon Fluorolog 3 at 488 nm 
excitation and 605 nm emission wavelengths for the SNPs and with 
Fluostar Optima at 584 nm excitation and 680 nm emission wave-
lengths for Evans blue-albumin. The apparent permeability coeffi-
cients (Papp, cm/s) were calculated as described previously [27] by 
the following equation: 
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Briefly, Papp was calculated from the concentration difference of the 
nanoparticles in the lower or acceptor compartment (Δ[C]A) after 4 
hours and [C]D is the concentration in the donor (upper) compart-
ments at 0 hour, and VA is the volume of the acceptor compartment 
(1.5 mL), and A is the surface area available for permeability (1.1 
cm2). 
2.2.8. RNA Isolation and Quality Control 
 Rat brain microvessels were isolated as described in our previ-
ous article [28]. Primary brain endothelial cells (isolated and cul-
tured according to the method described in our previous studies [28, 
29]) and hCMEC/D3 cells were cultured for 5 days in 10 cm dishes. 
After reaching confluency cells were scraped and collected by cen-
trifugation. Microvessel and cell pellets were used for total RNA 
isolation using RNAqueous-4PCR Kit (Ambion, Life Technologies, 
Austin, TX, USA) with DNase1 (RNase-free) treatment according 
to the manufacturer’s instructions. The concentrations and purity of 
the DNase-treated RNA samples was assessed by a NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Rockland, DE). 
The integrity of the isolated RNA was checked by Bioanalyzer 
2100 (Agilent Technologies, Santa Clara, CA). The RNA integrity 
number (RIN) was 9.2-10 in the case of all studied RNA samples. 
2.2.9. Quantitative Real-Time Polimerase Chain Reaction and 
Data Analysis 
 Quantitative real-time PCR (RT-PCR) and data analysis were 
performed as described in our previous study [30]. The cDNA syn-
thesis was performed on 1 µg total RNA samples by High Capacity 
cDNA Reverse Transcription Kit (Life Technologies) using random 
hexanucleotides primers and MultiScribe Reverse Transcriptase in 
the presence of RNase inhibitor according to the manufacturer’s 
standard protocols. The expression of the SMVT/SLC5A6 vitamin 
transporter gene was analyzed by quantitative PCR using TaqMan 
Low Density Array 384-well microfluidic cards preloaded with 
inventoried TaqMan Gene Expression Assays (for hCMEC/D3 
human brain cells: Hs00221573_m1, for rat brain cells: 
Rn00590633_m1; Life Technologies). RT PCRs were performed by 
ABI TaqMan Universal Master Mix (Life Technologies) using the 
ABI Prism 7900 system (Applied Biosystems, Life Technologies). 
RT-PCR data were analyzed using the ABI SDS 2.0 software (Ap-
plied Biosystems, Life Technologies). In all samples the expression 
of genes was normalized to 18S rRNA, which was used as an en-
dogenous control (ΔCt = Ctgene - Ct18S rRNA). Expression values 
reflecting the activity of studied genes were determined based on 
the normalized expression of genes calculated with 2-∆Ct formula 
which were correlated to the lowest normalized expression meas-
ured by the applied RT-PCR method. For quantification of relative 
expression level of genes of interest the normalized expression data 
were analyzed using the comparative ∆∆Ct method. 
2.2.10. Statistical Analysis 
 Data are presented as means ± SEM or SD. Values were com-
pared using one-way or two-way analysis of variance following 
Dunnett or Bonferroni multiple comparison posttests (GraphPad-
Prism 5.0; GraphPad Software, USA). Changes were considered 
statistically significant at P < 0.05. All experiments were repeated 
at least two times, the number of parallel samples was 4-8. 
3. RESULTS 
 Table 1 summarizes the main physicochemical characteristics 
of the untargeted and targeted SNPs (for schematic drawing see  
Fig. 1).  
Table 1. Characterization of the non-targeted and targeted 
solid nanoparticles. 
Nanoparticle Size (nm) 
Polydispersity 
index 
Zeta potential 
(mV) 
SNP 93 ± 0.59 0.131 ± 0.02 -14 ± 0.87 
SNP-B 118.1 ± 2.9 0.251 ± 0.001 -23.1 ± 0.62 
SNP-B-GSH 120.5 ± 2.86 0.261 ± 0.01 -23.8 ± 1.33 
 
 Values presented are means ± SD. SNP, non-targeted solid 
nanoparticles; SNP-B, biotin-targeted solid nanoparticles; SNP-B-
GSH, glutathione-targeted solid nanoparticles. 
 The commercially available solid fluorescent particles (nominal 
size of 40 nm) were already functionalized with neutravidin which 
enlarged the SNPs. These neutravidin-coated particles were labeled 
with biotin and glutathione which further increased their size. All 
SNPs had low polydispersity index, indicating a relatively narrow 
size distribution. The average zeta potential for both targeted parti-
cles was very similar. The charge of the non-labeled SNP was less 
negative. The morphology of the nanoparticles was observed by 
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SEM and shown on Fig. 2. The particles had mostly spherical 
shapes, but some SNPs were elongated. The size of the SNPs were 
all in the same range, and corresponds well to data measured by 
dynamic light scattering. No aggregation was visible.  
3.1. Effect of SNPs on the Cell Viability of Brain Endothelial 
Cells 
 Incubation of the brain endothelial monolayers with SNP and 
SNP-B in the 10-1000 µg/mL concentration range for 24 hours had 
no effect on cell viability assessed by MTT dye conversion (Fig. 3). 
As a comparison, the reference substance Triton X-100 detergent 
decreased the cell viability below 10% of the control values. SNP-
B-GSH (30-100 µg/mL) increased the metabolic activity of cells, 
while the highest concentration (1000 µg/mL) caused a reduction in 
viability (Fig. 3). For further experiments we selected the 150 
µg/mL concentration for all three SNPs, which can be considered as 
non-toxic. 
3.2. Uptake of SNPs in Brain Endothelial Cells 
 The uptake of SNPs in endothelial cells was tested at two time 
points (Fig. 4). In the design of our study we determined the time 
points for the uptake experiments based on the results of Gaillard et 
al. obtained on nanoparticles labeled with GSH, our reference 
ligand [31, 19, 20]. To be able to compare our data to these previ-
ous observations we selected 4 and 8 hours incubations. After 4 
hours of incubation no significant difference between the uptakes of 
three SNPs in brain endothelial cells could be measured, although 
an increasing trend was seen in case of targeted SNPs. After 8-hour 
incubation the uptake of all tested nanoparticles was significantly 
higher compared to the 4-hour group. Importantly the uptake of the 
biotin- and glutathione-targeted SNPs was significantly increased; it 
was two times higher than the uptake of the non-targeted particle. 
 The uptake of the fluorescent nanoparticles could be visualized 
in brain endothelial cells by confocal microscopy (Fig. 5). Red 
 
 
 
 
 
 
Fig. (1). Schematic drawing of non-targeted (SNP), biotin- (SNP-B) and glutathione-labeled (SNP-B-GSH) solid nanoparticles. 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Scanning electron microscopy images of non-targeted (A), biotin-targeted (B), and glutathione-targeted (C) solid nanoparticles. Bar: 100 nm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). The effect of non-targeted (SNP), biotin-targeted (SNP-B), and glutathione-targeted (SNP-B-GSH) solid nanoparticles on the viability of brain endo-
thelial cells (24 hours). Values presented are means ± SEM. Statistical analysis: one-way analysis of variance followed by Dunnett’s posttest, ** P < 0.01; *** 
P < 0.001 compared to control. n = 4-8. X-axis: log-10 scale. 
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fluorescent dots can be seen in the cytoplasm of the cells treated 
with SNPs. More fluorescent particles were seen in cells incubated 
with glutathione-labeled SNPs indicating better uptake of these 
nanoparticles as compared to the non-targeted SNPs.  
3.3. Penetration of SNPs Across Brain Endothelial Monolayers 
 The permeability of hCMEC/D3 brain endothelial cell mono-
layers for Evans blue-albumin was 1.6 ± 0.3 ×10-6 cm/s which was 
in the same range as in our previous study [32] and reflects a suit-
able barrier for testing SNPs. All SNPs crossed the brain endothe-
lial layers in the permeability tests but at different extent (Fig. 6). 
After 8-hour incubation the Papp of biotin targeted SNP was 2.8 fold 
higher than that of the non-targeted SNP. The penetration of the 
GSH targeted nanoparticles was the highest, a significant, 5.8 fold 
increase was measured as compared to the unlabeled SNP group. 
3.4. Expression of SMVT/SLC5A6 mRNA in Brain Microves-
sels and Cultured Brain Endothelial Cells 
 The expression level of SMVT/SLC5A6 vitamin transporter 
gene mRNA was expressed in isolated rat brain microvessels, and 
both in hCMEC/D3 human brain endothelial cell line and primary 
rat brain endothelial cells (Fig. 7). No statistically significant 
change was found in the mRNA expression level between the 
groups (one-way ANOVA and Bonferroni posttest). 
4. DISCUSSION 
 Although drug delivery systems to cross the BBB are an in-
tensely researched area there are no targeted nanoparticles in the 
human therapy yet to deliver therapeutics to the brain in a con-
trolled and non-invasive manner. Specific targeting can be achieved  
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Permeability changes of brain endothelial monolayers after SNP 
treatments (150 µg/mL, 8 h). Values presented are means ± SEM. Statistical 
analysis: one-way analysis of variance followed by Bonferroni posttest. *P 
< 0.05, ***P < 0.001, compared to non-labeled SNP treated group; ##P < 
0.01, compared to biotin-labeled SNP treated group, n = 6. 
 
through exploiting the physiological transport pathways of the BBB 
including the endogenous nutrient transporters of brain endothelium 
[2, 7]. Despite the abundance of carrier mediated transporters at the 
BBB this physiological pathway is still not fully exploited for drug 
delivery.  
 Biotin is a potential BBB targeting ligand, since it has a highly 
expressed carrier, SLC5A6, at the human BBB including 
hCMEC/D3 brain endothelial cells [23, 30]. We have verified the 
presence of SLC5A6 mRNA in hCMEC/D3 brain endothelial cells, 
which showed an expression level similar to isolated brain 
 
 
 
 
 
 
 
Fig. (4). The uptake of non-targeted (SNP), biotin-labeled (SNP-B) and glutathione-labeled (SNP-B-GSH) solid nanoparticles in brain endothelial cells after 4 
or 8 hours incubation. The concentration of SNPs is 150 µg/mL in each group. Values presented are means ± SEM. Statistical analysis: two-way analysis of 
variance followed by Bonferroni posttest, where **P < 0.01; ***P < 0.001, compared to SNP treated group, ##P < 0.01; ###P < 0.001, compared to the 4 hour-
incubation group; n = 4–6. 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Confocal microscopy images of cultured human brain endothelial cells incubated with non-labeled (A), biotin-labeled (B), and glutathione-labeled (C) 
solid nanoparticles (red) for 8 hours at 37 ºC. The concentration of SNPs is 150 µg/mL in each group. Cell nuclei were stained with bis-benzimide (blue). Bar: 
20 µm. 
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Fig. (7). The expression level of SMVT/SLC5A6 vitamin transporter gene 
mRNA in isolated rat brain microvessels (MV), hCMEC/D3 human brain 
endothelial cell line and primary rat brain endothelial cells (RBEC). 
 
microvessels and cultured primary brain endothelial cells. Biotin is 
a cofactor for several carboxylase enzymes and a cell growth pro-
moter. It cannot be synthesized endogenously in the brain therefore 
it is supplied from the blood across the BBB. The brain concentra-
tion of biotin is about 50-fold higher than that in the plasma [33].  
 Biotin technology based on the exceptionally strong binding 
between biotin and avidin has long been used in basic research for 
immunohistochemistry and molecular biology. Recently biotin-
avidin technology has been applied for drug targeting to tumors 
[24]. In several studies nanoparticles are biotinylated to easily de-
tect them on tissue slices with streptavidin-FITC [34]. Biotinylation 
of drugs is also used to bind them to avidin-functionalized particles 
[35]. However, none of the studies used biotin as a ligand for BBB 
targeting.  
 We prepared and characterized biotin- and glutathione-labeled 
SNPs from neutravidin-coated commercially available red fluores-
cent polystyrene particles. Labeling with biotin and biotin-
glutathione increased the particle size, in accordance with literature 
data on biotinylated albumin NPs [34]. The average size and sur-
face charge of the targeted SNPs were similar measured by dy-
namic light scattering. The heterogeneity seen by scanning electron 
microscopy may be related to the different batches of SNPs used for 
labeling. The size of NPs related to their cellular uptake and biodis-
tribution is widely studied. In general, particles with a size below 
100 nm can be taken up by all cells by endocytosis and are consid-
ered as high risk NPs from nanotoxicology point of view, especially 
if they are non-biodegradable [36]. These small NPs are non-
specifically taken up by the liver, lungs and kidneys. This is the 
reason why most NPs developed for possible therapeutic use has a 
size in the range of 100-200 nm. The glutathione targeted NPs used 
by Gaillard and his colleagues were also in this range, e.g. 108 nm, 
[31]; 95 nm, [20]. The size of SNPs used in this study fell also in 
this range. NPs larger, than 200 nm do not enter brain tissue [37]. In 
agreement with in vivo findings NPs with 400 nm size did not cross 
a culture BBB model [38]. 
 We are the first to demonstrate, that biotin-labeling increases 
the uptake and transfer of SNPs in human brain endothelial cells as 
compared to unlabeled particles. This finding is in agreement with 
active transport of biotin at the BBB in vivo [39] and in hCMEC/D3 
brain endothelial cell cultures [23]. An experimental study indicates 
that biotinylated NPs can enter the brain [34] and this targeting 
concept may work in vivo, too. Intravenously administered 
biotinylated albumin NPs could be detected in several brain regions 
of rats with experimental autoimmune encephalomyelitis using post 
mortem streptavidin-FITC labeling [34]. However, this observation 
may provide indirect support only, because the aim of this study 
was the visualization of albumin NPs in the CNS, and no data are 
available in control rats or with unlabeled albumin NPs.  
 We showed a high uptake for the biotinylated glutathione-
labeled SNPs in brain endothelial cells. Gaillard et al. proved in 
several studies the increased uptake of glutathione-labeled pegy-
lated liposomes in both cultured rat and human endothelial cells 
[31, 20]. We found that the transfer of glutathione-labeled SNPs 
across the in vitro BBB model was the highest among the tested 
particles and several fold higher than that of the non-targeted ones. 
Our results are in concordance with the in vivo data on the en-
hanced brain penetration of drugs and biopharmacons, including 
cytostatic doxorubicin, antiinflammatory methylprednisolone, 
opioid peptide DAMGO, and an anti-amyloid antibody by glu-
tathione-labeled vesicular NPs. Glutathione as a vector not only 
increased the brain delivery of doxorubicin (543 Da) in rats [21], 
but it also inhibited tumor growth and increased survival in a mouse 
model of glioblastoma multiforme [20]. Brain uptake of methyl-
prednisolone (374 Da) was elevated by glutathione targeting [19], 
and improved therapeutic efficacy was described for GSH-
pegylated liposomal methylprednisolone in experimental autoim-
mune encephalomyelitis in rats [19], in mice [40], and in ocular 
inflammation in rats [41]. Increased brain delivery was demon-
strated for the opioid pentapeptide DAMGO (513 Da) by GSH-
pegylated liposomes in rats [22]. Enhanced GSH-pegylated liposo-
mal brain delivery of a llama single domain anti-amyloid antibody 
fragment (15 kDa) was demonstrated in a mouse model for Alz-
heimer's disease [42], indicating that the platform may also be used 
for CNS delivery of biopharmacons. 
 Targeted NPs may use several transport routes at the BBB as 
reviewed by Rempe et al. [43]. Solid NPs were described to cross 
brain endothelial cells by receptor- or adsorption-mediated transcy-
tosis [36, 43]. The higher transfer of SNP-B and SNP-B-GSH parti-
cles may be related to transcytosis due to the binding of targeting 
ligands to the surface of the brain endothelial cells. Indeed, we have 
verified the presence of SMVT/SLC5A6 mRNA in hCMEC/D3 
brain endothelial cells, our BBB model system. In the case of biotin 
targeted SNPs, we hypothesize that the targeting ligand helps the 
binding of the nanocarriers to the surface of brain endothelial cells, 
which triggers transcytosis across the brain endothelial monolayers. 
For the clinical-stage GSH drug delivery platform, although the 
BBB receptor/transporter is unknown, the suggested mechanism of 
BBB crossing is a secific liposomal endocytosis pathway indicative 
of receptor-mediated transcytosis [19]. Further experiments are 
needed to explore the exact mechanism.  
CONCLUSION 
 Biotin as a ligand increased the uptake and the transfer of 
nanoparticles across brain endothelial cells and may have a poten-
tial to be used as a BBB targeting molecule. Biotinylated glu-
tathione was more effective as a ligand to increase nanoparticle 
permeability through endothelial monolayers supporting its use as 
successful brain targeting vector. 
LIST OF ABBREVIATIONS 
ACN = Acetonitrile 
B = Biotin 
BBB = Blood-brain barrier 
DCC = N,N-dicyclohexyl-carbodiimide  
DCM = Dichloromethane  
DIEA = N,N-diisopropylethylamine  
DMF = N.N-dimethylformamide  
DTT = 1,4-dithiothreitol  
Fmoc = 9-flourenylmethyloxycarbonyl  
GSH = Glutathione 
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HATU = 1-[Bis(dimethylamino)methylene]-1H-1,2,3-
triazolo[4,5-b]pyridinium 3-oxid hexafluoro-
phosphate  
hCMEC/D3 = Human brain endothelial cell line 
HOBt = 1-hydroxybenzotriazole  
HPLC = High performance liquid chromathography 
MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide 
NP = Nanoparticle 
SLC = Solute carrier transporter 
SNP = Solid nanoparticle 
SNP-B = Biotin targeted solid nanoparticle 
SNP-B-GSH = Biotinylated-glutathione targeted solid nanopar-
ticle 
TFA = Triflouroacetic acid  
TIS = Triisopropylsilane 
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